We present here correlative studies performed as part of the first-in-child New Approaches to Neuroblastoma Therapy (NANT) Consortium Phase 1 study (NANT2015-02) of lorlatinib in children, adolescents, and adults with ALK-driven refractory/relapsed neuroblastoma32. The gene discussed is ALK; the disease is neuroblastoma.